Form 4: Elanco Director Lawrence Kurzius Reports Changes in Beneficial Ownership

Director Lawrence Kurzius reports acquisition of deferred stock units in Elanco Animal Health Inc. through a director deferral plan.

Summary

• On December 31, 2024, Lawrence Kurzius, a director of Elanco Animal Health Inc., acquired 4,954.583 deferred stock units.
• These units were obtained through the company's Directors' Deferral Plan, where director cash retainer fees are deferred and credited to the Elanco Deferred Stock Account.
• Each deferred stock unit is equivalent to one share of Elanco common stock.
• The price of Elanco common stock on the grant date (December 31, 2024) was $12.11.
• Following the reported transaction, Mr. Kurzius beneficially owns 38,567.1413 deferred stock units.
• The deferred stock units will be settled in stock after Mr. Kurzius' separation of service from the Company's Board of Directors.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard director compensation practices and aligns director interests with the company's long-term performance.

Future Outlook

The deferred stock units will be settled in stock following the reporting person's separation of service from the Company's Board of Directors pursuant to the Plan.

Industry Context

This filing reflects standard compensation practices for directors, often involving deferred stock units to align their interests with long-term shareholder value.

Stakeholder Impact

• The transaction aligns the director's interests with those of shareholders by linking compensation to the company's stock performance.

Key Dates